Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.79 |
| ▸ | PTGFR | P43088 | 14/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.61 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19851521 | 0.90 | PTGFR (0.67) | SLCO2A1PTGFRKDM4EMEN1ABCB11 | |
| Latanoprost Acid SCHEMBL12087458 | 0.89 | SLCO2A1 (1.00) | SLCO2A1PTGFRKDM4EMEN1ABCB11 | |
| Latanoprost Acid SCHEMBL12076372 | 0.89 | SLCO2A1 (1.00) | SLCO2A1PTGFRKDM4EMEN1ABCB11 | |
| Latanoprost Acid SCHEMBL1514745 | 0.89 | SLCO2A1 (1.00) | SLCO2A1PTGFRKDM4EMEN1ABCB11 | |
| Latanoprost Acid SCHEMBL1313162 | 0.89 | SLCO2A1 (1.00) | SLCO2A1PTGFRKDM4EMEN1ABCB11 | |
| Latanoprost Acid SCHEMBL12608975 | 0.89 | SLCO2A1 (1.00) | SLCO2A1PTGFRKDM4EMEN1ABCB11 | |
| Latanoprost Acid SCHEMBL19847192 | 0.89 | SLCO2A1 (1.00) | SLCO2A1PTGFRKDM4EMEN1ABCB11 | |
| Latanoprost Acid SCHEMBL1313159 | 0.89 | SLCO2A1 (1.00) | SLCO2A1PTGFRKDM4EMEN1ABCB11 | |
| Latanoprost Acid SCHEMBL21087135 | 0.89 | SLCO2A1 (1.00) | SLCO2A1PTGFRKDM4EMEN1ABCB11 | |
| Latanoprost Acid SCHEMBL12458743 | 0.89 | SLCO2A1 (1.00) | SLCO2A1PTGFRKDM4EMEN1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956302-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180036416-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036416-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | SLCO2A1 1556/4885PTGFR 24/4885KDM4E 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.